Authors
Latest:
Leticia Tordesillas, PhD, on the Potential of γδ CAR T-cells to Treat Bone Metastatic Prostate CancerThe research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.
Latest:
Future Research With Stem Cell Therapies in Hematologic MalignanciesThe chief executive and chief medical officers of Vor Biopharma discussed the company’s future research and plans.
Latest:
Alexandra Lisi on Scaling Manufacturing Efficiency to Support Cell TherapyThe cell therapy field applications staff scientist at ThermoFisher discussed advantages of the company’s DynaCellect system.
Latest:
Surbhi Sidana, MD, on Assessing Ide-cel in Patients With R/R Multiple Myeloma and Renal ImpairmentThe assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study.
Latest:
IND for Gene Replacement Therapy for Inherited Retinal Dystrophy Cleared by FDAThe company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.
Latest:
Later-Generation Cell Therapies Increase Utility in Hematologic MalignanciesCAR T-cell therapy use will likely expand to a wider array of hematologic malignancies.
Latest:
Jay Spiegel, MD, FRCPC, on 5-Year Real-World Outcomes From Axi-cel in R/R LBCLThe hematologist and cell therapist from the University of Miami Sylvester Comprehensive Cancer Center spoke about long-term outcome data he presented at ASH’s 2023 conference.
Latest:
Veit Bücklein, Dr Med, on Research Trends in Hematological Malignancy Cell TherapyThe postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.
Latest:
Targeting Progranulin With Gene Therapy for Frontotemporal DementiaWilliam Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.
Latest:
Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple MyelomaThe director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.
Latest:
Jay Barth, MD, on Ascidian Therapeutics' Developments in Gene TherapyCGTLive's sister publication spoke with Barth, the chief medical officer at Ascidian, about the company’s attempts to develop a new method of administration for gene therapy at ARVO 2023.
Latest:
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and AccessibilityThe pediatric neurologist at Nemours Children’s Health discussed next steps in the field to fully enable the benefits of gene therapy.
Latest:
Sung-Yun Pai, MD, on Further Research With Lentiviral Gene Therapy for X-SCIDThe senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.
Latest:
Evan Mizerak, on Developing an ASO Targeting CAPN2 for ALSThe lead of preclinical research at Amylyx Pharmaceuticals discussed the literature supporting AMX0114’s target and its upcoming trial design.
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Allogeneic Stem Cell Transplant for Acute Myeloid LeukemiaThe hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Latest:
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell DevelopmentThe associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
Latest:
Aliya Rashid, DO, MPH, on Further Research With Gender Inequality in CAR T Paper AuthorshipThe internal medicine resident physician at University of Kansas Medical Center also discussed highlights from the ASH 2023 meeting.
Latest:
Matthew B. Harms, MD, on the Necessity of Tracking Gene Mutations in ALSThe associate professor of neurology at Columbia University spoke about the importance of identifying patients with ALS-associated gene mutations as early as possible.
Latest:
Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple MyelomaSaad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.
Latest:
Julie Kanter, MD, on Highest Priorities for Sickle Cell After Gene Therapy ApprovalsThe director of the Adult Sickle Cell Clinic and associate professor at University of Alabama Birmingham pointed out access to a sickle cell specialist as one such priority.
Latest:
Del-Zota for Duchenne Muscular DystrophyMichael Flanagan, PhD, the chief scientific officer at Avidity, discussed the function and mechanism of the investigational antisense treatment, which is in development for DMD amenable to exon 44 skipping.
Latest:
Levi Gray-Rupp, PhD, on Using Integrated Circuit T-Cells Against Solid TumorsThe senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.
Latest:
Mantle Cell Lymphoma Outcomes May Improve With Bispecific CD20/CD19-targeted CAR T-cell TherapiesNirav N. Shah, MD, associate professor at the Medical College of Wisconsin in Milwaukee, discussed the evaluation of LV20.19 CAR in MCL, as well as key efficacy and safety data on the therapy to date.
Latest:
Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple MyelomaThe clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.
Latest:
Slowing Tumor Growth in Glioblastoma With Novel AAV TherapyLisa Nieland, a PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen, discussed her work presented at the ASGCT 2024 meeting.
Latest:
Stacy Lindborg, PhD, on Addressing Unmet Needs in ALS With Cell TherapyThe co-CEO of BrainStorm Cell Therapeutics spoke about the current standards of care in ALS and the potential of NurOwn to address unmet needs.
Latest:
Early Signals of Efficacy With Cystic Fibrosis Gene TherapyJennifer L. Taylor-Cousar, MD, MSCS, a professor of internal medicine and pediatrics at National Jewish Health discussed updated data from the phase 1/2 AEROW trial of 4D-710.
Latest:
Maria Escolar, MD, on the Importance of Newborn Screening for Treating Krabbe DiseaseThe chief medical officer of Forge Biologics discussed how expanded newborn screening practices may help the company’s gene therapy for Krabbe disease, FBX-101, reach more patients.
